ImmunityBio Inc News - IBRX | ADVFN

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

ImmunityBio Inc (IBRX)

5.44

0.24

(4.62%)

At close: November 05 4:00PM

Delayed by 15 minutes

5.48

0.04

( 0.74% )

After Hours: 6:08PM

Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma

Company’s first clinical trial studying CAR-NK (CD19 t-haNK) cellular therapy in liquid tumors First natural killer cell-based cellular therapy...

ImmunityBio to Participate in the Jefferies London Healthcare Conference

Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), announced today that company executives will be participating in the Jefferies London...

ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer

Phase 2 data presented at the World Conference on Lung Cancer showing a prolonged median overall survival of over 14 months in 2nd and 3rd line...

ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval

ANKTIVA® reaches U.S. commercial and Medicare insurance coverage milestone within three months of FDA approval Global expansion of commercial...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer

The QUILT 502 trial is testing ImmunityBio’s N-803 (ANKTIVA®) in combination with the AdHER2DC investigational vaccine for endometrial cancer, a...

Kuehn Law Encourages Investors of ImmunityBio, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of ImmunityBio, Inc. to Contact Law Firm PR Newswire NEW YORK, July 25, 2024...

Form 8-K - Current report

ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors

Multiple patients treated across the U.S. with ANKTIVA less than eight weeks after FDA approval of first-in-class cytokine immunotherapy for BCG...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

1
Next

glenn1919

glenn1919 1 week ago

IBRX........................https://stockcharts.com/h-sc/ui?s=IBRX&p=W&b=5&g=0&id=p86431144783

TrendTrade2016

TrendTrade2016 2 weeks ago

IBRX ROCKET SHIP

TrendTrade2016

TrendTrade2016 2 weeks ago

IBRX PUSH PUSH PUSH

glenn1919

glenn1919 2 weeks ago

IBRX...................................https://stockcharts.com/h-sc/ui?s=IBRX&p=W&b=5&g=0&id=p86431144783

TrendTrade2016

TrendTrade2016 2 weeks ago

tw0122

tw0122 2 weeks ago

Not bad $5.13 + 28%

jondoeuk

jondoeuk 4 weeks ago

A case report. From it: ''Here, we report the compassionate use treatment of this combination in a patient with recurrent, metastatic pancreatic cancer (mPC) after 3 lines of therapy. Under the initial single-patient Investigational New Drug (spIND) protocol, the patient received N-803, PD-L1 t-haNK cells, and the albumin doxorubicin conjugate aldoxorubicin for ~27 months. The patient's disease became stable on this regimen, and a transient complete response was observed by ~14 months of therapy. Due to progression, a second spIND protocol was designed whereby the patient received E-EDV-D682 plus EDV-GC for more than 24 months, which resulted in stable disease and the patient's continued survival at the time this report was written.'' https://academic.oup.com/oncolo/advance-article/doi/10.1093/oncolo/oyae267/7814737

aBeezlee

aBeezlee 1 month ago

$2 would be great. We'll see.

Bourbon_on_my_cornflakes

Bourbon_on_my_cornflakes 1 month ago

Wait until it hits $2.50

Hold!

axelvento

axelvento 2 months ago

bouncer$ ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer

https://immunitybio.com/immunitybio-presents-positive-long-term-overall-survival-data-in-non-small-cell-lung-cancer-patients-and-announces-registrational-intent-phase-3-trials-with-anktiva-and-checkpoint-immunotherapy/

Monksdream

Monksdream 2 months ago

Bourbon_on_my_cornflakes

Bourbon_on_my_cornflakes 3 months ago

Down and down, is approval for other cancer expected in June dead?

Bourbon_on_my_cornflakes

Bourbon_on_my_cornflakes 3 months ago

Why did IBRX tank so badly in mid August?

Bourbon_on_my_cornflakes

Bourbon_on_my_cornflakes 3 months ago

IBRX at $4

Wow. Where is the pancreatic cancer approval expected in June?

Monksdream

Monksdream 3 months ago

Monksdream

Monksdream 4 months ago

jgrabar

jgrabar 4 months ago

Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of ImmunityBio, Inc. (IBRX)
See https://grabarlaw.com/the-latest/immunitybio-shareholder-investigation/

tw0122

tw0122 5 months ago

09:45 AM EDT, 06/20/2024 (MT Newswires) -- ImmunityBio (IBRX) said Thursday that it has launched Anktiva, its immunotherapy to treat Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer, with multiple patients across the US receiving the initial commercial doses.

The US Food and Drug Administration approved Anktiva in April to treat patients with BCG-unresponsive non-muscle invasive bladder cancer with or without papillary tumors, according to ImmunityBio.

Bourbon_on_my_cornflakes

Bourbon_on_my_cornflakes 5 months ago

Any thoughts on how much revenue FDA approval will bring?

wrk_SATX

wrk_SATX 5 months ago

Still +54M shares short and time is ticking. 80% inside ownership with a small float.

saigai

saigai 6 months ago

up and down.. no problem.. ima staying put

saigai

saigai 6 months ago

we know there is a very large short position here.. i think that since the earnings post yesterday and the reaction to it that there is now very little reason to stay short,,lets see that spike

carldfw

carldfw 6 months ago

Pancreatic Cancer next!!
I like Oncolytics on that list

Tahoe2468

Tahoe2468 6 months ago

7. ImmunityBio Inc (NASDAQ:IBRX)
Float Shorted: 40.37%

With over 53 million of its shares shorted, ImmunityBio Inc’s (NASDAQ:IBRX) short interest stands at 40.37% as of April 8.

jondoeuk

jondoeuk 6 months ago

From Jan 19, 2023: ''ImmunityBio also announced that it held two productive Type B meetings with the FDA in December. The first was to present the recent data and obtain guidance toward a registration pathway in metastatic pancreatic cancer.'' https://www.businesswire.com/news/home/20230119005337/en/ImmunityBio-Announces-Presentation-at-ASCO-GI-2023-of-Fully-Enrolled-Trial-in-Third-Line-and-Greater-Pancreatic-Cancer-and-Update-on-FDA-Type-B-Meetings-Regarding-Paths-to-Registration

What happened?

jondoeuk

jondoeuk 6 months ago

Nothing listed in the pipeline.

Tahoe2468

Tahoe2468 6 months ago

Pancreatic Cancer next!! WOW!!

https://www.prnewswire.com/news-releases/biotechs-role-in-addressing-the-pancreatic-cancer-emergency-302089052.html

TrendTrade2016

TrendTrade2016 6 months ago

IBRX monster bio on the weekly break out

MiamiGent

MiamiGent 6 months ago

IBRX Friday Close $7.35+$2.24 (+43.84%)

This morning Pre-Mkt
Bid x Size
$8.13 x 2
Ask x Size
$8.20 x 212
Volume
862,349
90 Day Avg. Vol.
4,851,152

Bona fide squeeze underway. Millions of shares short are trapped.

carldfw

carldfw 6 months ago

Pancreatic will be even better!!In January 2023, ImmunityBio announced that it held two meetings with the FDA in December 2022 to present data and get guidance on a registration pathway for metastatic
pancreatic cancer
. The company's combination immunotherapy
, Nant Cancer Vaccine, has shown potential effectiveness in pancreatic cancer, more than doubling median overall survival (OS) compared to historical OS.

martind18

martind18 6 months ago

That’s because IHUB is for pump and dumps.

Atom Smasher

Atom Smasher 6 months ago

Good ole ihub. We have a REAL company here with a remarkable game changing cancer drug whose stock price will not only explode but retain it's stock price and no one here is even talking about it. As per my experience here several years ago.......everyone here is only interested in shells and scam companies. What a shame. That's fine. I'll be making bank. Join me if you want.......or don't. I'm not selling till it's somewhere above 40

Monksdream

Monksdream 6 months ago

This a simple bar/volume with 60-minute intervals

The stock is actually trading counter to a recent bearish trend for most tickers according my bit of DD from the Barchart website that would be considered med tech companies
This a link for the sector that is made up 459 tickers
https://www.barchart.com/stocks/quotes/IBRX/competitors?quoteSectors=-MEBI&viewName=main&orderBy=weightedAlpha&orderDir=desc

I have a free membership so I can use the flipcharts function for the past six months of price discovery
One can observe from the sector graph at the top of the page the best time to buy any old med stock was last November
The best time to sell was at the peak last March which isn’t that long ago
I can observe the same recurring pattern in the more than 200 tickers I flipped through

Atom Smasher

Atom Smasher 6 months ago

https://www.barchart.com/stocks/quotes/IBRX/opinion

Monksdream

Monksdream 6 months ago

IBRX in the Barchart Top 10
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

axelvento

axelvento 6 months ago

Anktiva is the next-generation immunotherapy drug, according to ImmunityBio executive chairman Dr. Patrick Soon-Shiong: "This drug is the first drug, as far as I know, that activates the natural killer cell that talks to the T-cell and generates complete remission..." pic.twitter.com/DIVc3A8luy— Yahoo Finance (@YahooFinance) April 23, 2024

Pt3

Pt3 6 months ago

martind18

martind18 6 months ago

FDA approval!

https://www.investorsobserver.com/news/qm-news/8088196297645818

axelvento

axelvento 7 months ago

The FDA has accepted the BLA resubmission and will now review the therapy. It has set a Prescription Drug User Fee Act (PDUFA) date of 23 April 2024.

Monksdream

Monksdream 8 months ago

Spideyboy

Spideyboy 8 months ago

Just curious, having read this article from June 2022, what makes us think that they will get approval for Antikva.

My concern just stems from the bottom of the article stating.

"Other drugs are in late-stage trials in combination with BCG for the same patient population, including AstraZeneca’s Imfinzi (durvalumab) and Sesen Bio’s Vicinium (oportuzumab monatox). The FDA previously rejected Sesen Bio’s BLA for the treatment of BCG-unresponsive patients, citing multiple issues, including a lack of randomised data comparing Vicinium with an investigator’s choice of intravesical chemotherapy."
https://www.pharmaceutical-technology.com/analyst-comment/immunitybio-first-marketed-drug/?cf-view

There is no comparator in the Antikva trial with any intravesical chemotherapy either, or against anything for that matter. As it's open-label single arm trial, with only Antikva being used. Will this be enough for FDA approval?

I know the prior CRL didn't mention anything about this, but that doesn't mean it isn't a potential issue?

Looking to be convinced wrong on the above :)

Monksdream

Monksdream 8 months ago

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

brogers_1

brogers_1 9 months ago

Research tool: https://tradingtimeline.com/ibrx.html

martind18

martind18 10 months ago

https://www.oberlandcapital.com/news-post/immunitybio-announces-320-million-investment-by-oberland-capital/

mick

mick 10 months ago

https://www.otcmarkets.com/stock/IBRX

pilotnick

pilotnick 11 months ago

This stock is ready to breakout, did awesome today!!

mick

mick 1 year ago

https://www.otcmarkets.com/stock/IBRX

da_stock_analyst

da_stock_analyst 1 year ago

#IBRX 🔥 this stock can go crazy with 30% short interest! $IBRX

da_stock_analyst

da_stock_analyst 1 year ago

#IBRX 🔥 30% short interest and gap fill possibilities for big move! $IBRX

gail

gail 1 year ago

yup, i see that but….

….

i didnt like how each time it runs, they yank it right back down, so i moved on but im happy it ran for you some. just be careful, they dont seem to last long.

Delayed Upgrade Clock

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions